S-2
S-2 Symposium: Corneal Collagen Crosslinking: Where Are We Now and What Does the Future Hold?
Narrative Responses:
Abstract
Sponsored by the ASCRS FDA Committee
Moderator: Michael W. Belin, MD, Chair
ASCRS FDA Committee
Panelists: Wiley Chambers
Deputy Director of the Division of Transplant and Ophthalmology Products, Center for Drug Evaluation and Research, Food and Drug Administration
Sheraz M. Daya, MD, FACS
Chairman and Medical Director, Centre for Sight
Doyle Stulting, MD, PhD
Director, Stulting Research Center, Professor of Ophthalmology, Emory University
William J. Link, PhD
Managing Director, Versant Ventures
Simon J. Dean, FRANZCO, FBCLA
Associate, Eye Institute Vision Correction Specialists
The 2014 FDA Symposium will focus on corneal collagen crosslinking. The session will feature remarks from Wiley Chambers, Deputy Director of the Division of Transplant and Ophthalmology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, who will address why the approval process is ongoing and the current status of corneal crosslinking in the United States.
Panelists will discuss the current available data on corneal collagen crosslinking. The discussion will also provide a summary of regulatory constraints on approval of this procedure and what it would take to get corneal crosslinking approved.